Time points (quarter) |
1 |
21.1 (16.4–27.1) |
<.0001 |
2 |
15.4 (11.9–19.8) |
<.0001 |
3 |
8.7 (6.7–11.3) |
<.0001 |
4 |
6.3 (4.8–8.1) |
<.0001 |
5 |
4.8 (3.7–6.2) |
<.0001 |
6 |
4.6 (3.5–5.9) |
<.0001 |
7 |
3.8 (2.9–4.9) |
<.0001 |
8 |
3.6 (2.7–4.6) |
<.0001 |
9 |
3.3 (2.6–4.3) |
<.0001 |
10 |
3.5 (2.7–4.6) |
<.0001 |
11 |
3.2 (2.5–4.2) |
<.0001 |
12 |
3.1 (2.4–4.1) |
<.0001 |
13 |
2.6 (2.0–3.4) |
<.0001 |
14 |
2.6 (2.0–3.4) |
<.0001 |
15 |
2.5 (1.9–3.2) |
<.0001 |
16 |
2.4 (1.8–3.1) |
<.0001 |
17 |
1.9 (1.5–2.5) |
<.0001 |
18 |
1.8 (1.4–2.4) |
<.0001 |
19 |
1.6 (1.2–2.2) |
0.0006 |
20 |
1.4 (1.1–1.9) |
0.01 |
21 |
1.3 (1.0–1.8) |
0.0424 |
22 |
1.3 (1.0–1.7) |
0.101 |
23 |
1.0 (0.8–1.4) |
0.7969 |
24 |
1.0 (.–.) |
. |
Age Group |
18 – 24 |
2.1 (1.6–2.6) |
<.0001 |
25 – 34 |
1.5 (1.3–1.7) |
<.0001 |
35 – 44 |
1.4 (1.3–1.5) |
<.0001 |
45 – 54 |
1.3 (1.2–1.3) |
<.0001 |
55 – 64 |
1.3 (1.2–1.3) |
<.0001 |
65 – 74 |
1.2 (1.1–1.2) |
<.0001 |
75 – 99 |
1.0 (.–.) |
. |
Gender |
Female |
0.8 (0.8–0.8) |
<.0001 |
Male |
1.0 (.–.) |
. |
Race |
White |
1.1 (1.1–1.2) |
0.0001 |
Black |
1.2 (1.2–1.3) |
<.0001 |
Hispanic |
1.1 (1.0–1.2) |
0.1077 |
Other |
1.0 (.–.) |
. |
Elixhauser Comorbidity |
Valvular disease |
1.2 (1.1–1.3) |
0.0002 |
Pulmonary circulation disease |
0.8 (0.8–0.9) |
0.0005 |
Peripheral vascular disease |
1.0 (0.9–1.1) |
0.3963 |
Hypertension |
0.9 (0.8–0.9) |
<.0001 |
Paralysis |
0.8 (0.7–0.9) |
<.0001 |
Other neurological disorders |
0.8 (0.7–0.8) |
<.0001 |
Chronic pulmonary disease |
0.9 (0.9–1.0) |
<.0001 |
Diabetes w/o chronic complications |
1.2 (1.1–1.2) |
<.0001 |
Diabetes w/chronic complications |
1.2 (1.2–1.3) |
<.0001 |
Hypothyroidism |
1.1 (1.0–1.1) |
0.001 |
Renal failure |
1.4 (1.3–1.4) |
<.0001 |
Liver disease |
1.0 (0.9–1.1) |
0.9721 |
Peptic ulcer Disease x bleeding |
0.7 (0.4–1.4) |
0.361 |
Acquired immune deficiency syndrome |
0.6 (0.4–0.8) |
0.0002 |
Lymphoma |
0.9 (0.8–1.1) |
0.3999 |
Metastatic cancer |
0.7 (0.6–0.8) |
<.0001 |
Solid tumor w/out metastasis |
0.8 (0.7–0.9) |
<.0001 |
Rheumatoid arthritis/collagen vas |
0.9 (0.8–1.0) |
0.0095 |
Coagulopthy |
1.2 (1.2–1.3) |
<.0001 |
Obesity |
1.1 (1.0–1.1) |
<.0001 |
Weight loss |
1.2 (1.1–1.3) |
<.0001 |
Fluid and electrolyte disorders |
1.4 (1.3–1.4) |
<.0001 |
Chronic blood loss anemia |
0.9 (0.8–1.0) |
0.0686 |
Deficiency Anemias |
1.0 (1.0–1.1) |
0.0256 |
Alcohol abuse |
1.1 (1.0–1.1) |
0.1291 |
Drug abuse |
1.0 (0.9–1.1) |
0.6205 |
Psychoses |
0.8 (0.8–0.9) |
<.0001 |
Depression |
0.9 (0.8–0.9) |
<.0001 |
Other AHRQ Comorbidity |
Disorders of lipid metabolism |
1.0 (1.0–1.1) |
0.0003 |
Coronary atherosclerosis and other heart disease |
1.4 (1.4–1.5) |
<.0001 |
Acute myocardial infarction |
1.4 (1.3–1.5) |
<.0001 |
Peripheral and visceral atherosclerosis |
1.1 (1.0–1.3) |
0.0307 |
Aortic; peripheral; and visceral artery aneurysms |
1.1 (1.0–1.2) |
0.1274 |
Aortic and peripheral arterial embolism or thrombosis |
1.1 (0.9–1.4) |
0.254 |
Transient cerebral ischemia |
0.8 (0.6–1.0) |
0.0568 |
Cardiac dysrhythmias |
1.3 (1.3–1.3) |
<.0001 |
Cardiac arrest and ventricular fibrillation |
1.1 (1.0–1.3) |
0.0023 |